This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): JNJ 61186372, EM1-mAb DuoBody, JNJ61186372
Description: JNJ-61186372 is a novel bispecific antibody targeting EGFR and cMET.
Genmab and Janssen
In July 2012, Genmab announced it has entered into a collaboration with Janssen to create and develop bispecific antibodies using its DuoBody technology platform. Genmab will create panels of bispecific antibodies to multiple disease target combinations identified by Janssen, who will in turn fully fund research at Genmab.
Under the terms of the agreement, Genmab and Janssen will collaborate on the research of up to 10 DuoBody programs and Genmab will receive an upfront payment of $3.5 million (DKK 21 million) from Janssen and all research by Genmab will be fully funded by Janssen. In addition, Genmab will potentially be entitled to milestone and license payments of up to approximately $175 million (DKK 1,062 million) for each product as well as royalties on any commercialized products.
In December 2013, Genmab announced an expansion of its collaboration with Janssen to create and develop bispecific antibodies using the DuoBody...See full deal structure in Biomedtracker
Partners: Genmab A/S
Additional information available to subscribers only: